Physician profile
Avinash Pasam
NPI 1750609582
$1,198.40
in general payments reported to CMS, 2019-2025
15 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.93 · 2022: $13.73 · 2023: $950 · 2024: $43.89 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,055 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,054.74 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $224.00 | 2023-2025 | Zynyz |
| Janssen Biotech, INC. | $202.41 | 2023 | Erleada, Tecvayli, Darzalex |
| Astrazeneca Pharmaceuticals Lp | $144.00 | 2021-2023 | Lynparza |
| Jazz Pharmaceuticals INC. | $125.71 | 2023 | Zepzelca |
| Seagen INC. | $124.99 | 2023 | Adcetris |
| Genzyme Corporation | $120.22 | 2023 | |
| Emd Serono, INC. | $99.99 | 2023 | Bavencio |
| Pharmacyclics LLC, An Abbvie Company | $37.02 | 2023 | Imbruvica |
| Exelixis INC. | $35.00 | 2022-2024 | Cabometyx |
| Abbvie INC. | $22.62 | 2024 | |
| Array Biopharma INC | $18.88 | 2025 | Mektovi, Braftovi, Lorbrena |
| Foundation Medicine, INC. | $16.10 | 2023 | Foundationone Cdx |
| Celgene Corporation | $15.54 | 2025 | Opdivo |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avinash Pasam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.